Knoxville, Tenn. – (September 15, 2014) – EDP Biotech Corporation, the US-based developer of ColoMarker®, a blood test to detect the early stages of colon cancer, today announced that widely recognized oncologist, Dr. William (Bill) H. West, and former Chairman, President and CEO of Regions Financial Corporation, Jackson (Jack) W. Moore, will be joining the company’s esteemed board of directors.
Dr. William (Bill) H. West is the Founder-Emeritus of the West Clinic in Memphis, Tenn., one of the largest cancer treatment programs in the southeast, and has published numerous articles in peer-reviewed medical literature. Dr. West is board certified in internal medicine and medical oncology, and has a career long interest in healthcare delivery systems. He is a graduate of Harvard College and The Johns Hopkins School of Medicine.
Jackson (Jack) W. Moore is a Director of Methodist LeBonheur Healthcare, one of the country’s largest private healthcare providers, based in Memphis, Tenn., and is also the retired Executive Chairman, President and CEO of Regions Financial Corporation, parent company of Regions Bank, and one of the nation’s largest regional financial companies. Mr. Moore currently serves as the the Vice Chairman of the Board of Trustees at Vanderbilt University. Previously, he had served as Chairman, President and CEO of Union Planters Corporation, based in Memphis, Tenn., prior to its merger with Regions Financial in 2004. He is also the former chair of the President’s Cabinet at the University of Alabama, where he earned a bachelor’s degree in banking and finance.
“It cannot be overstated how excited we are to add Dr. West and Jack Moore to our board of directors,” says Tom Boyd, Chairman of EDP Biotech. “Their experience in the industry and overall business acumen will be invaluable as we work to change the way physicians approach colon cancer diagnosis and management through our products.”
Dr. West and Mr. Moore will serve EDP Biotech alongside fellow board members: Tom Boyd, Chairman of the Board, EDP Biotech; Alan Jernigan, CEO, EDP Biotech, Jeff Peters, President and COO of The White Stone Group; Randy Boyd, Founder and President of Radio Systems Corporation (PetSafe™); Dr. Michael Spalding, 35-year licensed urologist in private practice in Nashville, Tenn.; and Douglas Yoakley, CPA and Co-Founder of regional CPA firm, Pershing Yoakley & Associates, which is headquartered in Knoxville, Tenn.
About EDP Biotech Corporation
EDP Biotech Corporation (EDP) is a privately held medical device company focused on the development and commercialization of immunodiagnostic tests for humans and animals. EDP performs research and develops products to identify and purify proteins present in the early stages of biological changes for production of in vitro diagnostic tests whose primary target is early detection.
EDP’s primary product, ColoMarker®, is a unique and proprietary biomarker measured by a simple blood test used in the early detection and monitoring of colorectal cancer. ColoMarker® has demonstrated an overall sensitivity for colon cancer detection of 95 percent and a specificity of 87 percent. The test is highly sensitive for detection of early stages of colorectal cancer when it is most treatable. Diagnostically, a positive assay result increases the odds of finding colorectal cancer by a factor of five. EDP plans to commercially launch the ColoMarker® test in the first half of 2015. For additional information, visit EDP Biotech online at www.edpbiotech.com.